$2,299.00 – $3,399.00
Indications for the drug Lynparza
Ovarian cancer
– Maintenance monotherapy for newly diagnosed advanced epithelial ovarian cancer, fallopian tube cancer, or high-grade primary peritoneal cancer with BRCA mutations in adult patients who have responded (complete or partial response) to first-line platinum-containing chemotherapy.
– Maintenance monotherapy for platinum-sensitive relapsed epithelial ovarian cancer, fallopian tube cancer, or high-grade primary peritoneal cancer in adult patients who have responded (complete or partial response) to platinum-containing chemotherapy.
Mammary cancer
– Metastatic HER2-negative breast cancer in adult patients with germline BRCA mutations who have previously received neoadjuvant or adjuvant chemotherapy or chemotherapy for metastatic disease.
Active ingredient: olaparib
Prescription medicine
| Дозировка | 100 Mg, 150 Mg |
|---|
